Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
Source: SeekingAlpha
2026-01-31 04:39:28 ET
...
Read the full article on Seeking Alpha
For further details see:
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
Benitec Biopharma Limited
NASDAQ: BNTC
BNTC Trading
17.06% G/L:
$12.76 Last:
194,348 Volume:
$11.34 Open:
BNTC Latest News
March 09, 2026 07:00:00 am
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
February 23, 2026 07:00:00 am
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
February 12, 2026 08:30:00 am
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
BNTC Stock Data
$403,180,255
15,517,473
0.09%
20
N/A
Biotechnology & Life Sciences
Healthcare
US
Hayward
